HSC-derived cell fate tracking

3 min read

March 17, 2020

nature neuroscience

The Cxcr4^{CreER(T2)-IRES-eGFP} Knockin mouse model as a universal tool to study functions of hematopoietic stem cell (HSC)-derived cells

Werner Y, et al. Cxcr4 distinguishes HSC‑derived monocytes from microglia and reveals monocyte immune responses to experimental stroke. Nat Neurosci. 2020

The Cxcr4 Knockin mouse model was designed and generated by genOway for a group of researchers, led by Prof. Ralf Stumm, who recently published their work in Nature Neuroscience.

By taking advantage of the CreER(T2)-IRES-eGFP design, the authors could distinguish HSC‑derived monocytes from tissue-resident microglia and macrophages, and demonstrate that Cxcr4 promotes initial monocyte infiltration and subsequent territorial restriction of monocyte-derived macrophages to infarct tissue.

This model is a powerful tool to:

Trace the lineage of HSC-derived cells such as monocytes and microglia, due to eGFP expression under the control of the Cxcr4 promoter
Track monocyte fate and function in injured brain tissues (e.g., experimental stroke), due to the inducible expression of Cre upon tamoxifen induction

Figure: Immunofluorescences for GFP, Iba1 and Tmem119 reveals the presence of Cxcr4⁺ cells after stroke induction in coronal brain sections. Interestingly, Cxcr4 is expressed in infiltrating monocytes, but not in reactive microglia.

Related products

Catalogue product

No items found.

Customized product

Reporter KI mouse

Use a reporter mouse Knockin for in vivo monitoring of transcriptional promoter activity, protein localization, cell trafficking, etc.

Other commentaries

Development of a new hSIRPα-specific radiotracer for non-invasive PET imaging using genOway’s double humanized hCD47/hSIRPα mouse and MC38-hPD-L1-hCD47-LZ cell line

Targeting the human CD47/SIRPα axis

Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model

CRS in BRGSF-HIS

A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Humanized VISTA mouse & Pharmacokinetics

Targeting myeloid cells in the tumor microenvironment in BRGSF-HIS mice

Myeloid compartment in BRGSF-HIS

Assessing T-cell engagers efficacy in vivo: Versatility of BRGSF-HIS mice

Assess T-cell engager in BRGSF-HIS

CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

Humanized ICP mouse and cell lines

Expression of druggable myeloid targets in the BRGSF-HIS preclinical model

Myeloid compartment in BRGSF-HIS

An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension

Humanized HSA/hFcRn mouse

Functional human myeloid compartment in BRGSF-HIS preclinical model

Myeloid compartment in BRGSF-HIS

A new promising family of small molecules regulating the PD-L1/PD-1 signaling pathway

Humanized PD-1/PD-L1 mouse and cell line

Assessing T-cell engagers in vivo: How BRGSF-HIS mice can help

Assess T-cell engager in BRGSF-HIS

Challenging the predictability of preclinical models for assessment of T-cell engagers

Assess T-cell engager in BRGSF-HIS

Targeting tumor-associated myeloid cells: The new grail in immuno-oncology?

Myeloid compartment in immuno-oncology

An alternative approach to immunotherapy: A bispecific agonist

Humanized PD-1 & GITR mouse

Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model

T-cell engager CD3

Relevant preclinical models to test T-cell engagers: The case of CD28

T-cell engager

Immunotherapy efficacy assessment and metastases studies: tHIS model is highly permissive to engraftment

Engraftments in BRGSF-HIS

A human-specific modifier of cortical connectivity and circuit function

Customized mouse model

NOTUM as alternative therapeutic approach to prevent clonal fixation and mutant expansion in patients predisposed to colorectal cancer

Customized mouse model

Cytokine release syndrome (CRS)

Assess T-cell engager in BRGSF-HIS

Tumor grafts in preclinical research: Models, models, overall, who is the fittest of them all?

Tumor-graft models

New doors to potential novel treatments for obesity

Customized mouse model

Uncoupling toxicity from therapeutic efficacy: the new challenge of immunotherapies

Assess toxicity with ICP

A novel preclinical and translational humanized CD3ε model to study the efficacy of T-cell engagers

T-cell engager

Define “humanized”: two mouse models helping produce cancer immunotherapies

Humanized mouse models

A Knockin C3-reporter mouse model represents a valuable tool to monitor C3 levels, a biomarker of inflamed versus uninflamed tissues

Customized mouse model

A VISTA on naive T cell fate

Humanized ICP mouse

A finely tuned crosstalk between enteric neurons and muscularis macrophages: evidence from a conditional Knockout mouse model developed by genOway

Customized mouse model

A new Nature report by Bristol-Myers Squibb provides new insights into VISTA biology and design of combination therapies

Humanized ICP in immuno-oncology

6 good reasons to employ our repository Knockout mouse models in your in vivo studies

Eucomm conditional Knockouts

Show all commentaries

Ultimate predictive models
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our models
Scientific excellence
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in France
Customer-centric
Tailor-made approach to your needs
Strong emphasis on customer satisfaction
Collaborative partner
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate

Customized model